Literature DB >> 224522

Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.

S I Ashida, Y Abiko.   

Abstract

Ticlopidine, when orally administered to rats, resulted in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme. In washed platelets, Ticlopidine also activated basal and PGE1-stimulated activity of the cyclase and prevented reduction in the cyclase activity caused by low concentrations of PGE2. Furthermore, Ticlopidine inhibited malondialdehyde formation in platelets induced by thrombin but failed to inhibit that caused by exogenous arachidonic acid. Adenosine 3',5'-cyclic monophosphate (c-AMP): phosphodiesterase activity of platelet lysate was not significantly affected by Ticlopidine treatment. These findings indicate that Ticlopidine inhibits platelet aggregation and prostaglandin synthesis from endogenous substrate through activating basal and PGE1-stimulated activity of the cyclase, preventing PGE2-induced depression of the cyclase activity and thus increasing platelet c-AMP level.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224522

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Authors:  G de Gaetano; V Bertelé
Journal:  Agents Actions       Date:  1984-01

2.  Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow.

Authors:  M Katashima; Y Yamada; K Yamamoto; H Kotaki; H Sato; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

3.  Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

Authors:  A Aukland; R A Hurlow; A J George; J Stuart
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

Review 4.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

5.  Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.

Authors:  G Di Minno; A M Cerbone; P L Mattioli; S Turco; C Iovine; M Mancini
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.